GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $14.00.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors [Yahoo! Finance]
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer [Yahoo! Finance]
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders [Yahoo! Finance]
Form 4 Monte Rosa Therapeutics, For: Dec 11 Filed by: Hughes Eric A
Form 3 Monte Rosa Therapeutics, For: Dec 11 Filed by: Hughes Eric A
Form 8-K Monte Rosa Therapeutics, For: Dec 11
Form 8-K Monte Rosa Therapeutics, For: Dec 05
Form SC 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.